Loading patent…
AssigneeUniversidade Federal De Mimas Gerais - UFMG
InventorsRuben Dario Sinisterra Millan, Robson Augusto Souza Dos Santos, Frederic Jean Georges Frezard, Washington Xavier De Paula
Estimating the term…
Preparation of AT1 receptors antagonists formulations using the cyclodextrins, their derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular disease and their complications. Until now, no applications using the AT11 receptor antagonists and cyclodextrins or derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular diseases and their complications, was found in the technical state of art. The present invention is characterized by the combination of two different technologies: one is the molecular encapsulation of AT11 receptor antagonists in cyclodextrins and the other is the microencapsulation in biodegradable polymers. It also comprises the increase of the effectiveness of the AT11 receptor antagonists as well as an increase in their bio-availability. The present invention comprises a new more effective alternative for the treatment of arterial hypertension, other cardiovascular diseases and their complications.
The formulations of ANGIOTENSIN II AT1 receptors antagonists characterized by the use of the cyclodextrins and their derivatives for the treatment of arterial hypertension, other cardiovascular diseases and its complications.
The formulations of ANGIOTENSIN II AT1 receptors antagonists characterized by the use of biodegradable polymers associated or not to cyclodextrins and their derivatives for the treatment of arterial hypertension and other cardiovascular diseases and its complications.
The formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins, their derivatives and the biodegradable polymers characterized by the increase of the duration and/or effectiveness of the antagonistic effect.
The formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins, their derivatives and the biodegradable polymers characterized by the increase of the antagonists bio-availability.
The formulations of angiotensin-(1-7) and/or losartan and its derivatives/analogues characterized for the use of the cyclodextrins and their derivatives and the biodegradable polymers for the treatment of arterial hypertension and other cardiovascular diseases and its complications.
The formulation of angiotensin-(1-7) and/or losartan and its derivatives/analogues with the cyclodextrins and their derivatives and the biodegradable polymers characterized by the increase of the duration and/or effectiveness of the antagonistic effect.
The formulation of angiotensin-(1-7) and/or losartan and its derivatives/analogues with the cyclodextrins and their derivatives and the biodegradable polymers characterized by the increase of the antagonists bio-availability.
Dependencies are inferred from the claim text.